<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Sheridan | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/tipmodem13/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/tipmodem13/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Sheridan.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">3d26ce82ffcc69764caae6cd9c773274</guid>
				<title>Sheridan posted an update: Natural alleles that control multiple disease resistance [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40561/</link>
				<pubDate>Fri, 07 Feb 2025 08:06:04 -0800</pubDate>

									<content:encoded><![CDATA[<p>Natural alleles that control multiple disease resistance (MDR) are valuable for crop breeding. However, only one MDR gene has been cloned in maize, and the molecular mechanisms of MDR remain unclear in maize. <a href="https://www.selleckchem.com/products/bda-366.html" rel="nofollow ugc">BDA-366 antagonist</a> In this study, through map-based cloning we cloned a teosinte-derived allele of a resistance gene, Mexicana lesion mimic&hellip;<span class="activity-read-more" id="activity-read-more-40561"><a href="http://www.nationalboardinstitute.com/activity/p/40561/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0a7a83fc20ec08b5cc0cf2affb5268aa</guid>
				<title>Sheridan posted an update: 32; 95% confidence interval [CI] 0.10-0.99; p = 0.049), [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31167/</link>
				<pubDate>Tue, 28 Jan 2025 16:20:43 -0800</pubDate>

									<content:encoded><![CDATA[<p>32; 95% confidence interval [CI] 0.10-0.99; p = 0.049), while the crude 14-day mortality did not differ between the two antibiotics (HR, 0.59; 95% CI 0.21-1.66; p = 0.32). The clinical success rate was higher with the use of ceftazidime-avibactam versus colistin (46.8% versus 20.4%, respectively; p = 0.047).</p>
<p> Ceftazidime-avibactam was&hellip;<span class="activity-read-more" id="activity-read-more-31167"><a href="http://www.nationalboardinstitute.com/activity/p/31167/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0ba4fdad55ca04c880567c4432ce5bce</guid>
				<title>Sheridan became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31130/</link>
				<pubDate>Tue, 28 Jan 2025 16:15:10 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>